Contact us to learn more about

our Premium Content: News alerts, weekly reports and conference planners

DRUG CLASS:

CDC7 kinase inhibitor

DRUG CLASS:

CDC7 kinase inhibitor

Contact us to learn more about our Premium Content:

News alerts, weekly reports and conference planners

Related drugs:

‹

›

TP53 mutation	Urothelial Cancer	TP53 mutation	Urothelial Cancer	LY3143921 Sensitive: C2 – Inclusion Criteria LY3143921 Sensitive : C2	LY3143921 Sensitive: C2 – Inclusion Criteria LY3143921 Sensitive : C2
TP53 mutation	Solid Tumor	TP53 mutation	Solid Tumor	LY3143921 Sensitive: C2 – Inclusion Criteria LY3143921 Sensitive : C2	LY3143921 Sensitive: C2 – Inclusion Criteria LY3143921 Sensitive : C2
PTPRC positive + KMT2A rearrangement	Acute Myelogenous Leukemia	PTPRC positive + KMT2A rearrangement	Acute Myelogenous Leukemia	SGR-2921 Sensitive: D – Preclinical SGR-2921 Sensitive : D	SGR-2921 Sensitive: D – Preclinical SGR-2921 Sensitive : D
TP53 mutation	Acute Myelogenous Leukemia	TP53 mutation	Acute Myelogenous Leukemia	SGR-2921 Sensitive: D – Preclinical SGR-2921 Sensitive : D	SGR-2921 Sensitive: D – Preclinical SGR-2921 Sensitive : D